Pre-Market Analysis: Amarin Corp. PLC, Elan Corp. PLC, Cubist Pharmaceuticals Inc., and Seattle Genetics Inc. PR Newswire LONDON, September 16, 2013 LONDON, September 16, 2013 /PRNewswire/ -- Editor Note: For more information about this release, please scroll to bottom. The U.S. equity market edged higher on Friday, September 13, 2013, with the S&P 500, the Dow Jones Industrial Average and the NASDAQ Composite rising 0.27%, 0.49% and 0.17%, respectively. Shares in the healthcare sector mostly ended on a higher note as the broader market advanced. The major movers in the sector included Amarin Corp. PLC (NASDAQ: AMRN), Elan Corp. PLC (NYSE: ELN), Cubist Pharmaceuticals Inc. (NASDAQ: CBST), and Seattle Genetics Inc. (NASDAQ: SGEN). All these companies are tracked by AAAResearchReports.com. Free technical research on AMRN, ELN, CBST, and SGEN can be downloaded upon signing up at: http://www.aaaresearchreports.com/register/ Amarin Corp. PLC.'s stock ended flat on Friday, even as the broader market ended higher. The company's shares vacillated between$6.49 and$6.71before finishing the day at the previous day's closing price of$6.60. A total of 3.24 million shares were traded, which is below the daily average volume of 4.18 million. Amarin Corp. PLC.'s shares have advanced 13.40% in the last one month, outperforming the S&P 500 which has gained 1.94% during the same period. Furthermore, the company's stock is trading above its 50-day moving average of $5.89. Sign up and read the complimentary report on AMRN at: http://www.AAAResearchReports.com/AMRN091613.pdf On Friday, Elan Corp. PLC's stock gained 0.46%, tracking gains in the broader market. The company's shares ended the day at$15.45 after fluctuating between$15.37 and$15.45. A total of 3.61 million shares were traded, which is less than the daily average volume of 11.53 million. Elan Corp. PLC's shares have advanced 13.10% in the last three months, compared to a gain of 3.77% in the S&P 500 during the same period. Additionally, the company's stock is trading near its 52-week high of $15.92 as well as above its 50-day and 200-day moving averages of $15.02 and $12.33, respectively. The free report on ELN can be downloaded by signing up now at: http://www.AAAResearchReports.com/ELN091613.pdf Cubist Pharmaceuticals Inc.'s shares edged lower on Friday, extending their losses from previous trading sessions. The company's shares traded between $64.60 and $65.55 before finishing the day 0.22% lower at $64.79. A total of 0.60 million shares were traded, which is below the daily average volume of 1.04 million. Despite Friday's pullback, the company's shares have advanced 5.14% in the last one month and 29.14% in the previous three months, compared to a gain of 1.94% and 3.77% in the S&P 500 during the respective periods. Additionally, Cubist Pharmaceuticals Inc.'s stock is trading near its 52-week high of $66.68 as well as above its 50-day and 200-day moving averages of $60.08 and $49.60, respectively. A free report on CBST can be accessed by registering at: http://www.AAAResearchReports.com/CBST091613.pdf Shares in Seattle Genetics Inc. edged higher on Friday, hitting a new 52-week high of $48.61. The company's shares closed the day at $48.48, up 0.58% from the previous day's price of $48.20. A total of 0.88 million shares were traded, which is below the daily average volume of 1.00 million. The company's shares have gained 18.01% in the last one month and 48.12% in the previous three months, outperforming the S&P 500 during the respective periods. Further, Seattle Genetics Inc.'s stock is trading above its 50-day and 200-day moving averages of $41.30 and $33.73, respectively. Register with AAA Research Reports and download research on SGEN for free at: http://www.AAAResearchReports.com/SGEN091613.pdf ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by an analyst. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. AAAresearchreports.com SOURCE AAA Research Reports Contact: + 1 (646) 396-9126 ; Contact Name: Peter F. Jones ; email@example.com
Pre-Market Analysis: Amarin Corp. PLC, Elan Corp. PLC, Cubist Pharmaceuticals Inc., and Seattle Genetics Inc.
Press spacebar to pause and continue. Press esc to stop.